Short answer
Aldeyra Therapeutics, Inc. (ALDX) filed an 8-K current report with the SEC on March 17, 2026 reporting Item 7.01 (Regulation FD Disclosure). FDA issued second Complete Response Letter (2026 CRL) for reproxalap dry eye NDA: cited lack of substantial evidence and "inconsistency of study results".
Aldeyra Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- FDA issued second Complete Response Letter (2026 CRL) for reproxalap dry eye NDA: cited lack of substantial evidence and "inconsistency of study results"
- FDA rejected despite prior dry eye chamber trial hitting primary endpoint (P=0.002): "totality of evidence does not support effectiveness"
- Aldeyra plans Type A meeting with FDA to determine path forward; additional studies likely required, raising costs and extending timeline materially
- No assurance FDA will ever approve reproxalap; company may also abandon pursuit for financial or strategic reasons
- Cash runway extended into 2028 as of Dec 31, 2025: provides time to navigate regulatory path but approval timeline remains highly uncertain
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aldeyra Therapeutics, Inc. 8-K filings
Get the next ALDX 8-K as it lands
Follow ALDX for push alerts, or ask the research agent what this filing means.